

Jun Pin Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2124111/publications.pdf>

Version: 2024-02-01

68
papers

2,152
citations

257450

24
h-index

254184

43
g-index

76
all docs

76
docs citations

76
times ranked

3344
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. <i>Journal of Digestive Diseases</i> , 2011, 12, 38-44.	1.5	227
2	Guidelines for the diagnosis and management of alcoholic liver disease: Update 2010. <i>Journal of Digestive Diseases</i> , 2011, 12, 45-50.	1.5	143
3	Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2. <i>Journal of Hepatology</i> , 2016, 65, 988-997.	3.7	134
4	Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. <i>Gut</i> , 2018, 67, 2169-2180.	12.1	114
5	Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1419-1425.	2.8	86
6	From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2271-2273.	2.3	79
7	Lactylation, a Novel Metabolic Reprogramming Code: Current Status and Prospects. <i>Frontiers in Immunology</i> , 2021, 12, 688910.	4.8	76
8	ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. <i>Scientific Reports</i> , 2015, 5, 16494.	3.3	72
9	Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. <i>Liver International</i> , 2015, 35, 2392-2400.	3.9	71
10	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study. <i>Hepatology</i> , 2014, 59, 1283-1292.	7.3	69
11	Toll-like receptor signaling in the progression of nonalcoholic fatty liver disease induced by high-fat and high-fructose diet in mice. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 482-488.	1.9	61
12	Neutrophils Play a Crucial Role in the Early Stage of Nonalcoholic Steatohepatitis via Neutrophil Elastase in Mice. <i>Cell Biochemistry and Biophysics</i> , 2015, 73, 479-487.	1.8	52
13	AKT/mTOR signaling pathway is involved in salvianolic acid B-induced autophagy and apoptosis in hepatocellular carcinoma cells. <i>International Journal of Oncology</i> , 2016, 49, 2538-2548.	3.3	48
14	Characterization of transcriptional modules related to fibrosing-NAFLD progression. <i>Scientific Reports</i> , 2017, 7, 4748.	3.3	48
15	Curcumin: A Promising Agent Targeting Cancer Stem Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 787-792.	1.7	44
16	Relationship of serum uric acid level with nonalcoholic fatty liver disease and its inflammation progression in nonobese adults. <i>Hepatology Research</i> , 2017, 47, E104-E112.	3.4	35
17	Increased ratio of neutrophil elastase to antitrypsin is closely associated with liver inflammation in patients with nonalcoholic steatohepatitis. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 13-21.	1.9	34
18	Randomized, Vitamin E-Controlled Trial of Bicyclol Plus Metformin in Non-Alcoholic Fatty Liver Disease Patients with Impaired Fasting Glucose. <i>Clinical Drug Investigation</i> , 2014, 34, 1-7.	2.2	31

#	ARTICLE	IF	CITATIONS
19	Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-16.	1.2	31
20	Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism. Biochemical and Biophysical Research Communications, 2019, 518, 691-697.	2.1	30
21	The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. Expert Review of Gastroenterology and Hepatology, 2019, 13, 385-395.	3.0	29
22	SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miRâ€23bâ€3p via sponging EGR1 in hepatocellular carcinoma. Cancer Medicine, 2020, 9, 4324-4338.	2.8	28
23	Metaâ€analysis: global prevalence, trend and forecasting of nonâ€alcoholic fatty liver disease in children and adolescents, 2000â€2021. Alimentary Pharmacology and Therapeutics, 2022, 56, 396-406.	3.7	28
24	Nonâ€alcoholic fatty liver disease (<scp>NAFLD</scp>) fibrosis score predicts 6.6â€year overall mortality of <scp>C</scp>hinese patients with <scp>NAFLD</scp>. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 643-649.	1.9	27
25	Randomized, threeâ€arm study to optimize lamivudine efficacy in hepatitis <scp>B</scp> e antigenâ€positive chronic hepatitis <scp>B</scp> patients. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 748-755.	2.8	26
26	The Mechanism Underlying the Influence of Indole-3-Propionic Acid: A Relevance to Metabolic Disorders. Frontiers in Endocrinology, 2022, 13, 841703.	3.5	26
27	Serum hepatitis <scp>B</scp> surface antigen quantification as a useful assessment for significant fibrosis in hepatitis <scp>B</scp> e antigenâ€positive hepatitis <scp>B</scp> virus carriers. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1746-1755.	2.8	25
28	Berberine ameliorates nonâ€alcoholic steatohepatitis in ApoE ^{-/-} mice. Experimental and Therapeutic Medicine, 2017, 14, 4134-4140.	1.8	23
29	Prediction of significant fibrosis and cirrhosis in hepatitis B eâ€antigen negative patients with chronic hepatitis <scp>B</scp> using routine parameters. Hepatology Research, 2013, 43, 441-451.	3.4	22
30	Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis. Obesity, 2019, 27, 2055-2066.	3.0	22
31	Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical and Translational Gastroenterology, 2021, 12, e00323.	2.5	22
32	The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma. Nature Communications, 2022, 13, 1363.	12.8	20
33	Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9. Cellular Physiology and Biochemistry, 2015, 37, 2405-2414.	1.6	19
34	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. Hepatology Research, 2018, 48, E213-E221.	3.4	19
35	Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice. American Journal of Translational Research (discontinued), 2019, 11, 2668-2682.	0.0	17
36	Association between nonalcoholic fatty liver disease and depression: A systematic review and meta-analysis of observational studies. Journal of Affective Disorders, 2022, 301, 8-13.	4.1	17

#	ARTICLE	IF	CITATIONS
37	Potential Regulators Driving the Transition in Nonalcoholic Fatty Liver Disease: a Stage-Based View. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 239-251.	1.6	16
38	Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 140.	2.4	15
39	Discovering master regulators in hepatocellular carcinoma: one novel MR, SEC14L2 inhibits cancer cells. <i>Aging</i> , 2019, 11, 12375-12411.	3.1	15
40	Prognostic performance of a series of model for end-stage liver disease and respective $\hat{\mu}$ scores in patients with hepatitis B acute-on-chronic liver failure. <i>Molecular Medicine Reports</i> , 2014, 9, 1559-1568.	2.4	14
41	Analysis of the <i>UGT1A1</i> Genotype in Hyperbilirubinemia Patients: Differences in Allele Frequency and Distribution. <i>BioMed Research International</i> , 2019, 2019, 1-9.	1.9	14
42	Activation of HIF-1 signaling ameliorates liver steatosis in zebrafish <i>atp7b</i> deficiency (Wilson's disease) models. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165842.	3.8	14
43	Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design. <i>Advances in Therapy</i> , 2016, 33, 2069-2081.	2.9	13
44	Linarin Enriched Extract Attenuates Liver Injury and Inflammation Induced by High-Fat High-Cholesterol Diet in Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-9.	1.2	13
45	Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. <i>Advances in Therapy</i> , 2018, 35, 218-231.	2.9	13
46	Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. <i>Obesity</i> , 2021, 29, 350-358.	3.0	13
47	TPGS-1000 exhibits potent anticancer activity for hepatocellular carcinoma in vitro and in vivo. <i>Aging</i> , 2020, 12, 1624-1642.	3.1	12
48	The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 426-432.	1.3	11
49	Genome-wide meta-analysis identifies susceptibility loci for autoimmune hepatitis type 1. <i>Hepatology</i> , 2022, 76, 564-575.	7.3	11
50	Abernethy malformation associated with Caroli's syndrome in a patient with a PKHD1 mutation: a case report. <i>Diagnostic Pathology</i> , 2017, 12, 61.	2.0	10
51	Ethanol extract of <i>Ligustrum lucidum</i> Ait. leaves suppressed hepatocellular carcinoma in vitro and in vivo. <i>Cancer Cell International</i> , 2019, 19, 246.	4.1	10
52	Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101876.	1.5	10
53	Chronic moderate alcohol consumption relieves high-fat high-cholesterol diet-induced liver fibrosis in a rat model. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 1046-1055.	1.9	9
54	Wnt/ β -catenin signaling was activated in supporting cells during exposure of the zebrafish lateral line to cisplatin. <i>Annals of Anatomy</i> , 2019, 226, 48-56.	1.9	9

#	ARTICLE	IF	CITATIONS
55	The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease. <i>Medical Science Monitor</i> , 2020, 26, e921887.	1.1	8
56	Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study. <i>Advances in Therapy</i> , 2019, 36, 880-895.	2.9	7
57	Comparing hepatic steatosis distribution patterns between non-alcoholic fatty liver disease and fatty liver disease with chronic hepatitis B by second-harmonic generation/two-photon excited fluorescence method. <i>Annals of Hepatology</i> , 2020, 19, 313-319.	1.5	7
58	The Role of Intestinal Fungi and Its Metabolites in Chronic Liver Diseases. <i>Gut and Liver</i> , 2020, 14, 291-296.	2.9	7
59	The Potential Role of Gut Microbial-Derived Exosomes in Metabolic-Associated Fatty Liver Disease: Implications for Treatment. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	7
60	Alagille syndrome caused by NOTCH2 mutation presented atypical pathological changes. <i>Clinica Chimica Acta</i> , 2021, 521, 258-263.	1.1	6
61	Prediction of hepatic necroinflammatory activity in patients with chronic hepatitis B by a simple noninvasive model. <i>Journal of Translational Medicine</i> , 2018, 16, 166.	4.4	5
62	Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Anatomical Record</i> , 2019, 302, 193-200.	1.4	5
63	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 212-226.	1.5	4
64	Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	3
65	FMO4 shapes immunometabolic reconfiguration in hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, e740.	4.0	3
66	The Accuracy and Clinical Relevance of the Multi-echo Dixon Technique for Evaluating Changes to Hepatic Steatosis in Patients with Non-alcoholic Fatty Liver Disease Treated with Formulated Food. <i>Magnetic Resonance in Medical Sciences</i> , 2023, 22, 263-271.	2.0	2
67	Study on the new strategy and key techniques for accurate prevention and treatment of nonalcoholic steatohepatitis based on intestinal target bacteria. <i>Medicine (United States)</i> , 2020, 99, e22867.	1.0	1
68	Identification and characterization of dynamically regulated hepatitis-related genes in a concanavalin A-induced liver injury model. <i>Aging</i> , 2020, 12, 23187-23199.	3.1	1